Jung Cassie
Jung Cassie, COO, reported a transaction classified as exercise at Aquestive Therapeutics, Inc. involving 4587.000000 shares for an estimated $4403.52. Reported holdings after the transaction were 206833.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Sep 03, 2026
- Filing date
- Sep 08, 2026
How reported position traded is calculated
Calculated only for code-P purchases and code-S sales.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
AQST price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- exercise Code X
- Identifier
- 0001214659-26-011475 Common Stock
- Transaction date
- Sep 03, 2026 Filed Sep 08, 2026, 08:06 PM · 5d delay
- Shares
- 4,587 sh $0.96 per share
- Estimated value
- $4.40k Computed from shares × price
- Holdings after
- 206,833 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
+6 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Chief Operating Officer
- F1
Represents the exercise for cash of a Common Stock Purchase Warrant issued to the Reporting Person on June 8, 2022 pursuant to a Securities Purchase Agreement dated June 6, 2022. The warrant became ex…
0 other transactions
0 recent txs